# INCIPIENT (NCT05660369)

> CARv3-TEAM-E T Cells in Glioblastoma

No report yet. It can be ordered.

- Drugs tested: CARv3-TEAM-E
- Indication: glioblastoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05660369
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Marcela V. Maus, M.D.,Ph.D.
- Conditions: Glioblastoma; Malignant Glioma; Recurrent Glioblastoma; Recurrent Glioma
- Interventions: CARv3-TEAM-E T cells
- Enrollment: 21
- Primary outcome: Incidence of Adverse Events (AEs)
- Primary outcome: Number of Dose-Limiting Toxicities (DLTs)

## Indexed commentary on INCIPIENT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=incipient-nct05660369